<p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的文件中表示，在第三季度将其在 Quest Diagnostics Incorporated (NYSE:DGX - 免费报告) 的持股减少了 73.2%。该机构投资者在季度内出售了 15,248 股后，持有该医疗研究公司 5,588 股股票。Assenagon Asset Management S.A. 在 Quest Diagnostics 的持股在最近一个季度末价值为 1,065,000 美元。</p>
<p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
<ul>
<li>Myriad Genetics 通过遗传癌症检测股价飙升</li>
</ul>
<p>其他对冲基金和机构投资者也买卖了该公司的股票。Oak Thistle LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 119.7%。Oak Thistle LLC 目前拥有 3,833 股该医疗研究公司的股票，价值 730,000 美元，此前在上个季度又购买了 2,088 股。Aaron Wealth Advisors LLC 在第三季度购买了 Quest Diagnostics 的新头寸，价值约为 1,452,000 美元。GAMMA Investing LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 17.4%。GAMMA Investing LLC 目前拥有 3,511 股该医疗研究公司的股票，价值 669,000 美元，此前在上个季度又购买了 520 股。Hobart Private Capital LLC 在第三季度获得了 Quest Diagnostics 的新股份，价值约为 564,000 美元。最后，Caldwell Trust Co 在第二季度购买了 Quest Diagnostics 的新股份，价值约为 346,000 美元。机构投资者持有该公司 88.06% 的股票。</p>
<h2>Quest Diagnostics 股价上涨 0.5%</h2>
<p>NYSE:DGX 的股票在周四以 175.92 美元开盘。该股票的 50 日简单移动平均线为 182.79 美元，200 日简单移动平均线为 179.89 美元。该公司的债务与股本比率为 0.71，速动比率为 1.04，流动比率为 1.13。Quest Diagnostics Incorporated 的一年低点为 148.70 美元，一年高点为 197.55 美元。该股票的市值为 195.7 亿美元，市盈率为 20.65，市盈增长比率为 2.36，贝塔值为 0.62。</p>
<ul>
<li>LifeMD 股价因 GLP-1 业务增长而回升</li>
</ul>
<p>Quest Diagnostics (NYSE:DGX - 获取免费报告) 最近于 10 月 21 日（星期二）公布了其财报。该医疗研究公司报告季度每股收益为 2.60 美元，超出市场共识预期的 2.51 美元，超出 0.09 美元。Quest Diagnostics 的净利润率为 8.91%，股本回报率为 15.47%。该公司在本季度的收入为 28.2 亿美元，而市场共识预期为 27.3 亿美元。在去年同期，该公司每股收益为 2.30 美元。与去年同期相比，该公司的季度收入增长了 13.2%。Quest Diagnostics 已将其 2025 财年的指引设定为每股收益 9.760-9.840。股票分析师预测 Quest Diagnostics Incorporated 今年的每股收益将达到 9.7。</p>
<h2>Quest Diagnostics 宣布分红</h2>
<p>该公司最近还宣布了一项季度分红，将于 1 月 28 日（星期三）支付。1 月 13 日（星期二）登记的股东将获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，收益率为 1.8%。该分红的除息日为 1 月 13 日（星期二）。Quest Diagnostics 的派息比率目前为 37.56%。</p>
<h2>内部买卖</h2>
<ul>
<li>Exact Sciences 正好满足投资者的期望</li>
</ul>
<p>在其他消息中，SVP Mark E. Delaney 于 11 月 18 日（星期二）出售了 7,946 股该公司的股票。该股票的平均售价为 187.35 美元，总交易额为 1,488,683.10 美元。交易后，该高级副总裁直接持有 7,530 股该公司的股票，价值约为 1,410,745.50 美元。这笔交易代表其持股减少了 51.34%。该出售在向证券交易委员会提交的文件中披露，可通过 SEC 网站访问。此外，SVP Michael E. Prevoznik 于 9 月 26 日（星期五）出售了 227 股该公司的股票。该股票的平均售价为 188.13 美元，总交易额为 42,705.51 美元。交易完成后，该高级副总裁直接持有 38,117 股该公司的股票，价值约为 7,170,951.21 美元。这代表其持股减少了 0.59%。该出售的披露信息可在 SEC 文件中找到。内部人士在过去九十天内出售了价值 12,631,382 美元的 65,998 股公司股票。内部人士持有该公司 8.16% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对该公司进行了评论。Barclays 将 Quest Diagnostics 的目标价从 190.00 美元上调至 195.00 美元，并在 10 月 22 日（星期三）的研究报告中给予该股票 “持平” 评级。瑞银集团将 Quest Diagnostics 的目标价从 180.00 美元上调至 190.00 美元，并在 10 月 17 日（星期五）的研究报告中给予该股票 “中性” 评级。Leerink Partners 将 Quest Diagnostics 的目标价从 203.00 美元上调至 210.00 美元，并在 10 月 21 日（星期二）的研究报告中给予该股票 “跑赢大盘” 评级。Weiss Ratings 在一份研究报告中重申了对 Quest Diagnostics 的 “买入（b-）” 评级。最后，Wall Street Zen 在 11 月 8 日（星期六）的报告中将 Quest Diagnostics 的评级从 “买入” 下调至 “持有”。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，十位分析师给予 “持有” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价为 197.27 美元。</p>
<p><strong>阅读我们最新的 DGX 股票报告</strong></p>
<h2>Quest Diagnostics 简介</h2>
<p>（免费报告）</p>
<p>Quest Diagnostics（纽约证券交易所代码：DGX）是领先的诊断信息服务提供商，支持患者、医生和医疗机构的临床决策。该公司运营着一个临床实验室和患者服务中心的网络，执行广泛的实验室测试和诊断分析，用于常规护理、疾病诊断、监测和筛查。</p>
<p>其服务涵盖核心临床实验室测试、解剖病理学、分子和基因组诊断、传染病检测和毒理学。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Quest Diagnostics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI 吧，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Quest Diagnostics 吗？</h2>
<p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前立即购买……而 Quest Diagnostics 并不在名单上。</p>
<p>虽然 Quest Diagnostics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

奎斯特诊疗

<p>Assenagon Asset Management S.A. 在第三季度将其在奎斯特诊疗的股份减少了 73.2%，目前持有 5,588 股，价值 1,065,000 美元。其他机构投资者也调整了他们的持仓。奎斯特诊疗报告第三季度每股收益为 2.60 美元，超出预期，收入同比增长 13.2%。该公司宣布每股季度分红为 0.80 美元。在过去 90 天内，内部人士出售了价值 1263 万美元的股份。该股票开盘价为 175.92 美元，市值为 195.7 亿美元</p>

<p>Assenagon Asset Management S.A. decreased its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 73.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,588 shares of the medical research company's stock after selling 15,248 shares during the quarter. Assenagon Asset Management S.A.'s holdings in Quest Diagnostics were worth $1,065,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Assenagon Asset Management S.A. 在最近向证券交易委员会提交的文件中表示，在第三季度将其在 Quest Diagnostics Incorporated (NYSE:DGX - 免费报告) 的持股减少了 73.2%。该机构投资者在季度内出售了 15,248 股后，持有该医疗研究公司 5,588 股股票。Assenagon Asset Management S.A. 在 Quest Diagnostics 的持股在最近一个季度末价值为 1,065,000 美元。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Quest Diagnostics</strong> 警报：</p>
</div><ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 通过遗传癌症检测股价飙升</li>
</ul>
</div><p>Other hedge funds and other institutional investors have also bought and sold shares of the company. Oak Thistle LLC grew its position in Quest Diagnostics by 119.7% during the 3rd quarter. Oak Thistle LLC now owns 3,833 shares of the medical research company's stock worth $730,000 after purchasing an additional 2,088 shares during the last quarter. Aaron Wealth Advisors LLC purchased a new position in Quest Diagnostics during the third quarter valued at approximately $1,452,000. GAMMA Investing LLC boosted its holdings in Quest Diagnostics by 17.4% during the third quarter. GAMMA Investing LLC now owns 3,511 shares of the medical research company's stock worth $669,000 after buying an additional 520 shares in the last quarter. Hobart Private Capital LLC acquired a new stake in shares of Quest Diagnostics during the 3rd quarter valued at about $564,000. Finally, Caldwell Trust Co purchased a new stake in shares of Quest Diagnostics in the second quarter valued at approximately $346,000. Institutional investors own 88.06% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金和机构投资者也买卖了该公司的股票。Oak Thistle LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 119.7%。Oak Thistle LLC 目前拥有 3,833 股该医疗研究公司的股票，价值 730,000 美元，此前在上个季度又购买了 2,088 股。Aaron Wealth Advisors LLC 在第三季度购买了 Quest Diagnostics 的新头寸，价值约为 1,452,000 美元。GAMMA Investing LLC 在第三季度将其在 Quest Diagnostics 的持股增加了 17.4%。GAMMA Investing LLC 目前拥有 3,511 股该医疗研究公司的股票，价值 669,000 美元，此前在上个季度又购买了 520 股。Hobart Private Capital LLC 在第三季度获得了 Quest Diagnostics 的新股份，价值约为 564,000 美元。最后，Caldwell Trust Co 在第二季度购买了 Quest Diagnostics 的新股份，价值约为 346,000 美元。机构投资者持有该公司 88.06% 的股票。</p>
</div><h2>Quest Diagnostics Stock Up 0.5%</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股价上涨 0.5%</h2>
</div><p>Shares of NYSE:DGX opened at $175.92 on Thursday. The stock has a 50-day simple moving average of $182.79 and a 200-day simple moving average of $179.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.04 and a current ratio of 1.13. Quest Diagnostics Incorporated has a 1 year low of $148.70 and a 1 year high of $197.55. The stock has a market capitalization of $19.57 billion, a P/E ratio of 20.65, a PEG ratio of 2.36 and a beta of 0.62.</p>
<div class="lb-trans"><p>NYSE:DGX 的股票在周四以 175.92 美元开盘。该股票的 50 日简单移动平均线为 182.79 美元，200 日简单移动平均线为 179.89 美元。该公司的债务与股本比率为 0.71，速动比率为 1.04，流动比率为 1.13。Quest Diagnostics Incorporated 的一年低点为 148.70 美元，一年高点为 197.55 美元。该股票的市值为 195.7 亿美元，市盈率为 20.65，市盈增长比率为 2.36，贝塔值为 0.62。</p>
</div><ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 股价因 GLP-1 业务增长而回升</li>
</ul>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its earnings results on Tuesday, October 21st. The medical research company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion during the quarter, compared to the consensus estimate of $2.73 billion. During the same period in the prior year, the firm earned $2.30 earnings per share. The business's quarterly revenue was up 13.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS. Equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.</p>
<div class="lb-trans"><p>Quest Diagnostics (NYSE:DGX - 获取免费报告) 最近于 10 月 21 日（星期二）公布了其财报。该医疗研究公司报告季度每股收益为 2.60 美元，超出市场共识预期的 2.51 美元，超出 0.09 美元。Quest Diagnostics 的净利润率为 8.91%，股本回报率为 15.47%。该公司在本季度的收入为 28.2 亿美元，而市场共识预期为 27.3 亿美元。在去年同期，该公司每股收益为 2.30 美元。与去年同期相比，该公司的季度收入增长了 13.2%。Quest Diagnostics 已将其 2025 财年的指引设定为每股收益 9.760-9.840。股票分析师预测 Quest Diagnostics Incorporated 今年的每股收益将达到 9.7。</p>
</div><h2>Quest Diagnostics Announces Dividend</h2>
<div class="lb-trans"><h2>Quest Diagnostics 宣布分红</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, January 13th. Quest Diagnostics's payout ratio is presently 37.56%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度分红，将于 1 月 28 日（星期三）支付。1 月 13 日（星期二）登记的股东将获得每股 0.80 美元的分红。这相当于每年 3.20 美元的分红，收益率为 1.8%。该分红的除息日为 1 月 13 日（星期二）。Quest Diagnostics 的派息比率目前为 37.56%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>Exact Sciences 正好满足投资者的期望</li>
</ul>
</div><p>In other news, SVP Mark E. Delaney sold 7,946 shares of the firm's stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $187.35, for a total transaction of $1,488,683.10. Following the transaction, the senior vice president directly owned 7,530 shares of the company's stock, valued at approximately $1,410,745.50. This trade represents a 51.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, SVP Michael E. Prevoznik sold 227 shares of the company's stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $188.13, for a total transaction of $42,705.51. Following the completion of the sale, the senior vice president directly owned 38,117 shares of the company's stock, valued at approximately $7,170,951.21. This represents a 0.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 65,998 shares of company stock valued at $12,631,382 in the last ninety days. Insiders own 8.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，SVP Mark E. Delaney 于 11 月 18 日（星期二）出售了 7,946 股该公司的股票。该股票的平均售价为 187.35 美元，总交易额为 1,488,683.10 美元。交易后，该高级副总裁直接持有 7,530 股该公司的股票，价值约为 1,410,745.50 美元。这笔交易代表其持股减少了 51.34%。该出售在向证券交易委员会提交的文件中披露，可通过 SEC 网站访问。此外，SVP Michael E. Prevoznik 于 9 月 26 日（星期五）出售了 227 股该公司的股票。该股票的平均售价为 188.13 美元，总交易额为 42,705.51 美元。交易完成后，该高级副总裁直接持有 38,117 股该公司的股票，价值约为 7,170,951.21 美元。这代表其持股减少了 0.59%。该出售的披露信息可在 SEC 文件中找到。内部人士在过去九十天内出售了价值 12,631,382 美元的 65,998 股公司股票。内部人士持有该公司 8.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts recently commented on the company. Barclays boosted their price target on Quest Diagnostics from $190.00 to $195.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, October 22nd. UBS Group raised their price objective on Quest Diagnostics from $180.00 to $190.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 17th. Leerink Partners increased their price target on shares of Quest Diagnostics from $203.00 to $210.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of Quest Diagnostics in a research report on Monday. Finally, Wall Street Zen lowered Quest Diagnostics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $197.27.</p>
<div class="lb-trans"><p>几位分析师最近对该公司进行了评论。Barclays 将 Quest Diagnostics 的目标价从 190.00 美元上调至 195.00 美元，并在 10 月 22 日（星期三）的研究报告中给予该股票 “持平” 评级。瑞银集团将 Quest Diagnostics 的目标价从 180.00 美元上调至 190.00 美元，并在 10 月 17 日（星期五）的研究报告中给予该股票 “中性” 评级。Leerink Partners 将 Quest Diagnostics 的目标价从 203.00 美元上调至 210.00 美元，并在 10 月 21 日（星期二）的研究报告中给予该股票 “跑赢大盘” 评级。Weiss Ratings 在一份研究报告中重申了对 Quest Diagnostics 的 “买入（b-）” 评级。最后，Wall Street Zen 在 11 月 8 日（星期六）的报告中将 Quest Diagnostics 的评级从 “买入” 下调至 “持有”。一位分析师给予该股票 “强烈买入” 评级，七位分析师给予 “买入” 评级，十位分析师给予 “持有” 评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，平均目标价为 197.27 美元。</p>
</div><p><strong>Read Our Latest Stock Report on DGX</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 DGX 股票报告</strong></p>
</div><h2>Quest Diagnostics Profile</h2>
<div class="lb-trans"><h2>Quest Diagnostics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.</p>
<div class="lb-trans"><p>Quest Diagnostics（纽约证券交易所代码：DGX）是领先的诊断信息服务提供商，支持患者、医生和医疗机构的临床决策。该公司运营着一个临床实验室和患者服务中心的网络，执行广泛的实验室测试和诊断分析，用于常规护理、疾病诊断、监测和筛查。</p>
</div><p>Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.</p>
<div class="lb-trans"><p>其服务涵盖核心临床实验室测试、解剖病理学、分子和基因组诊断、传染病检测和毒理学。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Quest Diagnostics</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI 吧，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Quest Diagnostics 吗？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Quest Diagnostics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄向客户推荐在更广泛的市场注意到之前立即购买……而 Quest Diagnostics 并不在名单上。</p>
</div><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Quest Diagnostics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Assenagon 资产管理公司降低了其在奎斯特诊疗公司 $DGX 的持股比例